FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington.	D.C.	20549	

	OMB APPRO	VAL
Ì	OMB Number:	3235-0287
	Estimated average burden	ı
	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

DURHAM NC 27713 (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 2. Transaction Date (Month/Day/Year) (
(Last) (First) (Middle) 2525 EAST NORTH CAROLINA HIGHWAY 54 (Street) DURHAM NC (City) (State) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 2. Transaction (Month/Day/Year) (City) (State) Table I - Non-Derivative Securities Acquired, Disposed of (D) (Instr. 3) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) 2. Transaction Code (Instr. 3) 3. A Deemed Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) Securities Seneficially Owned Following Reported (D) or Indirect (D) or Indirec			Person*						mbol		(Checl	k all applicable)	,	
(Street) DURHAM NC 27713 Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 2. Transaction Date, (Month/Day/Year) 3. Date of Earliest Transaction (Month/Day/Year) 4. If Amendment, Date of Original Filed (Month/Day/Year) 5. Individual or Joint/Group Filing (Check Applicable X Form filed by One Reporting Person Form filed by More than On														
DURHAM NC 27713 (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 2. Transaction Date (Month/Day/Year) (,	` ,	54	` ' '										
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 2. Transaction Date (Month/Day/Year) (Month	· ·					endment, Date of C	Original I	Filed (Month/Day/Year	- 1	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) (Mon	(City)	(State)	(Zip)											
Date (Month/Day/Year) if any (Month/Day/Year) (Month/Day/Year) Date if any (Month/Day/Year) Date if any (Month/Day/Year) Disposed Of (D) (Instr. 3, 4 and 5) Securities Form: Direct (D) or Indirect Beneficially Owned Following Reported			Table I - N	on-Deriv	ative S	Securities Acq	uired,	Dis	posed of, or	Bene	ficially (Owned		
	1. Title of Security (Instr. 3)		Date		Execution Date, if any	Transaction Code (Instr.		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 a		() or 4 and 5)	Securities Beneficially Owned Following	Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership	
Code V Amount (C) Price (Instr. 3 and 4)					Code	v	Amount	(A) or (D)	Price	Transaction(s)		(Instr. 4)		
Common Stock 08/26/2021 A 1,148,240 A (1) 1,148,240 I By Spo	Common Stock			08/26/	/2021		A		1,148,240	A	(1)	1,148,240	I	By Spouse
	Common Stock			08/26/	/2021		A		18,930,004	A	(1)	18,930,004	I	By Ayabudge LLC
	Common Stock	ī.		08/26/	/2021		P		1,522,500	A	\$10	20,452,504	I	By Ayabudge LLC
Common Stock 810,161 D	Common Stock											810,161	D	

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Number Derivative Securities Acquired (or Dispose (D) (Instr. 3 and 5)	A)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Stock Options (right to buy)	\$2.56	08/26/2021		A		13,129		(2)	09/01/2025	Common Stock	13,129	(3)	13,129	D	
Stock Options (right to buy)	\$6.54	08/26/2021		A		17,068		(2)	04/12/2028	Common Stock	17,068	(3)	17,068	D	
Stock Options (right to buy)	\$1.19	08/26/2021		A		262,596		(2)	11/22/2023	Common Stock	262,596	(3)	262,596	I	By Spouse
Stock Options (right to buy)	\$2.56	08/26/2021		A		13,129		(2)	09/01/2025	Common Stock	13,129	(3)	13,129	I	By Spouse
Stock Options (right to buy)	\$2.56	08/26/2021		A		157,558		(2)	03/09/2026	Common Stock	157,558	(3)	157,558	I	By Spouse
Stock Options (right to buy)	\$3.44	08/26/2021		A		262,596		(2)	09/14/2026	Common Stock	262,596	(3)	262,596	I	By Spouse
Stock Options (right to buy)	\$6.54	08/26/2021		A		131,298		(2)	04/12/2028	Common Stock	131,298	(3)	131,298	I	By Spouse
Stock Options (right to buy)	\$10.28	08/26/2021		A		1,312,984		11/09/2021 ⁽⁴⁾	01/14/2031	Common Stock	1,312,984	(3)	1,312,984	I	By Spouse
Stock Options (right to buy)	\$10.28	08/26/2021		A		1,575		12/14/2021 ⁽⁵⁾	12/14/2030	Common Stock	1,575	(3)	1,575	I	By Spouse

Explanation of Responses:

2. Options are fully vested and exercisable.

- 3. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc.
- 4. One-third of the option will vest on each of the three anniversaries after November 9, 2020.
- 5. Options to purchase 2,625 shares of Common Stock granted on 12/14/2020, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Accordingly, columns 5, 7, and 9 of Table II report the number of securities equal to three-fifths of the 12/14/2020 option grant.

/s/ Brady W. Dougan by Dale A. Sander as Attorney-in-Fact

08/27/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.